Drug-induced liver injury (DILI) is a significant concern in clinical practice, arising from medications, herbs, and dietary ...

Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis ...

More than 1,000 different drugs are thought to cause liver damage and one French study estimated the global annual incidence rate of drug-related liver damage as 8 cases per 100,000 inhabitants ...

Bile duct inflammation and scarring, known as cholangiopathies, can disrupt bile flow, leading to liver damage and ...

Mirum Pharmaceuticals, Inc. today announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI® ...

Treatment of this autoimmune liver disease should also address various symptoms and complications arising from any associated autoimmune diseases, particularly cholestasis and cirrhosis-related ...

Chemomab Therapeutics (CMMB) announced results from the Open Label Extension portion of the Phase 2 SPRING trial assessing nebokitug as a ...

Ursodeoxycholic acid (UDCA), a widely used treatment for cholestatic liver diseases ... which help protect against mitochondrial damage. Furthermore, UDCA reduces inflammation by modulating ...

Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This ...

If you are consistently scritching and scratching, though, it’s important to tell a health care provider so that they can rule out a condition called cholestasis of pregnancy, a liver disease ...